## REGN: Regeneron Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.15 indicates fundamental undervaluation. Quality metrics strong (ROE 15%). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-12.1% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($697.22)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)**
- Source: GlobeNewswire | 20251201T070000 | Bullish | Relevance: 99%
- Regeneron Pharmaceuticals and Tessera Therapeutics announced a global collaboration to develop and commercialize TSRA-196, an investigational gene editing therapy for Alpha-1 Antitrypsin Deficiency (AATD). Tessera will receive $150 million upfront and an equity investment from Regeneron, with potential for an additional $125 million in milestone payments. The companies will share development costs and future profits equally, aiming to bring a one-time, durable treatment for AATD to patients.

**2. Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors**
- Source: MarketWatch | 20251201T163000 | Neutral | Relevance: 99%
- Shares of Regeneron Pharmaceuticals Inc. (REGN) declined by 3.86% on Monday, closing at $750.11. This drop occurred during a generally negative trading day for the stock market, with both the S&P 500 Index and Dow Jones Industrial Average also experiencing losses. This marked the third consecutive day of losses for Regeneron's stock.

**3. Regeneron and Tessera advance TSRA-196 toward IND/CTA filings**
- Source: CRISPR Medicine News | 20251201T185059 | Bullish | Relevance: 99%
- Regeneron Pharmaceuticals and Tessera Therapeutics are partnering to develop and commercialize TSRA-196, Tesseraâ€™s Gene Writing therapeutic for alpha-1 antitrypsin deficiency (AATD). Tessera plans to file an IND application with the U.S. FDA and multiple CTAs by the end of the year, positioning TSRA-196 to be the first Gene Writing-enabled treatment in clinical development. Preclinical data shows robust and durable genome editing in non-human primates and therapeutic correction in a mouse model, supporting its potential as a one-time correction for SERPINA1 mutations.

**4. Inceptionr LLC Invests $328,000 in Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251201T105153 | Somewhat-Bullish | Relevance: 98%
- Inceptionr LLC has invested $328,000 in Regeneron Pharmaceuticals (NASDAQ:REGN) by acquiring 624 shares in Q2. This comes amidst Regeneron beating Q3 earnings expectations with an EPS of $11.83 and revenue of $3.75 billion. The article also details other institutional investments, recent insider selling, and analyst ratings, with the stock holding a "Moderate Buy" consensus.

**5. Quadrant Capital Group LLC Sells 688 Shares of Regeneron Pharmaceuticals, Inc. $REGN**
- Source: MarketBeat | 20251202T110652 | Somewhat-Bullish | Relevance: 98%
- Quadrant Capital Group LLC reduced its stake in Regeneron Pharmaceuticals by 25.6% during the second quarter of 2025 by selling 688 shares, ending with 2,004 shares valued at $1.05 million. Regeneron recently surpassed earnings expectations with $11.83 EPS and $3.75 billion in revenue, maintaining strong profitability. Analysts rate REGN a "Moderate Buy" with an average target price of $757.91, and the company announced a quarterly dividend of $0.88.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $745 | $700 | +6% |
| 2025-12-04 | Canaccord Genui | $1057 | $850 | +24% |
| 2025-12-04 | BMO Capital | $850 | $725 | +17% |
| 2025-12-03 | Morgan Stanley | $767 | $767 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-04 | Canaccord Genui | main | Buy |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-12-03 | Morgan Stanley | down | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($20.86M) |
| Sells | 5 ($11.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (-4.0%)
- Blackrock Inc.: 8.6% (-4.7%)
- JPMORGAN CHASE & CO: 7.9% (+106.7%)
- State Street Corpora: 4.5% (-2.9%)
- Dodge & Cox Inc.: 4.4% (+18.9%)

### Key Risks

1. Heavy insider selling: $11M sold (5 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 5 raises (avg +16%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.15 suggests fair value with growth premium. Quality metrics strong (margin 32%). Balance sheet: strong liquidity (4.1x), low leverage (D/E 0.30), $1.4B free cash flow. Analyst sentiment positive (5 raises, avg +16%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $77.0B |
| Beta | 0.37 |
| 52W Range | $476.49 - $790.98 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.15 |
| Forward P/E | 18.8 |
| Current P/E | 17.2 |
| YoY Growth | -8.5% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 14.8% to 2.6% (-12.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.4pp (needs >4.0% for momentum thesis). MRS_5 (-4.1%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 4.5% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.86), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.62% (CS: 82) | Neutral |
| RSI_14 | 62.3 | Neutral |
| MACD Histogram | 0.86 | Bullish |
| vs SMA20 | 1.045x | Above |
| vs SMA50 | 1.165x | Above |
| vs SMA200 | 1.240x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $742.00
- **Stop Loss:** $697.22 (6.0% risk)
- **Target:** $831.56 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 22
- **Position Value:** $16,324.00
- **Portfolio %:** 16.32%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-03 (Est: $10.77)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.64 | $11.83 | +22.7% |
| 2025Q2 | $8.44 | $12.89 | +52.7% |
| 2025Q1 | $8.48 | $8.22 | -3.0% |
| 2024Q4 | $11.19 | $12.07 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*